Conferences
Breast Cancers
GI Cancers
Gynecologic Cancer
Immunology News
Multiple Myeloma
Hematology
Lymphoma
Leukemia
Lung Cancers
Melanoma
Prostate Cancer
Urology
CLL
Precision Medicine
Supportive Care
More...
Giants Cancer Care

Dr. Perez-Soler on Treatment Options for NSCLC

Roman Perez-Soler, MD
Published Online: Tuesday, February 14, 2012
Roman Perez-Soler, MD, Chairman, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, talks about the recent advances in treatment options for non-small cell lung cancer (NSCLC).

Perez-Soler states that targeted agents represent the most dramatic changes in the treatment of NSCLC. New agents are available that target subgroups with molecular alterations in EGFR and ALK. These alterations are driver mutations in tumor cells and as a result render high response rates.

Despite the initial response to a medication most tumors will eventually develop resistance. The next step for research is to understand how these tumors develop these resistance mechanisms.

Online CME Activities
Free CME from PER
Advances in Multiple Myeloma
Cancer Summaries and Commentaries™: Update from Chicago: Castrate Resistant Prostate Cancer and Advanced Melanoma
Community Practice Connections™: Novel Perspectives in Personalizing EGFR-Targeted Therapy in NSCLC: Frontline and Overcoming Resistance
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Gynecologic Cancers
More Reading
 
$auto_registration$